In the Phase 3 clinical trial of Zasositinib, the primary endpoints were achieved at week 16, with more than half of patients reaching PASI 90 and approximately 30% achieving PASI 100 indicating complete clearance of skin lesions. Safety profile was favorable.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4502-20260120-01.pdf","jir_short_summary":"In the Phase 3 clinical trial of Zasositinib, the primary endpoints were achieved at week 16, with more than half of patients reaching PASI 90 and approximately 30% achieving PASI 100 indicating complete clearance of skin lesions. Safety profile was favorable.","jir_summary":"### Regarding the Correction of Clinical Trial Results\nA translation error was identified in the Phase 3 clinical trial data of Zasositinib published on 2025-12-18, requiring correction of descriptions comparing placebo and apremilast. After correction, superiority over placebo is still demonstrated in the primary endpoints at week 16, sPGA0\/1 and PASI 75.\n\n### Phase 3 Clinical Trial Results of Zasositinib and Future Outlook\nIn an international joint Phase 3 study targeting moderate to severe plaque psoriasis patients, primary endpoints were achieved at week 16. More than half of patients attained PASI 90, and about 30% achieved PASI 100 indicating complete clearance of skin lesions, with effects lasting up to 24 weeks. The safety profile was favorable with no new safety signals observed. Applications for new drug approval will be submitted to regulatory authorities including the US FDA going forward.","jir_financial_highlights":"PASI 90 Achievement Rate: More than half (Unknown)\nPASI 100 Achievement Rate: Approximately 30% (Unknown)\nNumber of Patients in Phase 3 Clinical Trials: 693 and 1108 cases (Unknown)","jir_category":"","jir_hashtags":"#TakedaPharmaceuticalCompanyLimited, #product_announcement, #Zasositinib, #PlaquePsoriasis, #ClinicalTrial","jir_key_figures":"PASI 90 Achievement Rate: More than half (at week 16)\nPASI 100 Achievement Rate: Approximately 30% (at week 16)\nNumber of Patients in Phase 3 Clinical Trials: 693 and 1108 cases (total for 2 trials)","jir_meta_title":"Takeda Announces Correction: Over Half Achieve PASI 90 and Approximately 30% Achieve PASI 100 in Zasositinib Phase 3 Trial","jir_meta_description":"Takeda Pharmaceutical Company Limited has announced a partial correction to the Phase 3 clinical trial data of Zasositinib. At week 16, over half of patients achieved PASI 90, about 30% achieved PASI 100 with complete skin lesion clearance, and safety remained favorable. Regulatory submission to FDA planned.","jir_og_title":"Takeda Announces Correction to Zasositinib Phase 3 Trial Data","jir_og_description":"Takeda announces correction to Phase 3 clinical trial data showing improvement in skin lesions in plaque psoriasis patients with Zasositinib. Primary endpoints achieved and safety profile remained favorable.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-19956","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n